Prostatic transitional cell carcinoma: pathologic features and clinical management

Expert Rev Anticancer Ther. 2007 Aug;7(8):1155-62. doi: 10.1586/14737140.7.8.1155.

Abstract

Prostatic involvement by transitional cell carcinoma (pTCC) in patients with bladder cancer is a frequent finding, particularly in patients with high-grade invasive tumor and urothelial carcinoma in situ. Various patterns and levels of prostatic involvement have been described, and their impact in patients' management and their prognosis recognized. The role of prostatic urethral biopsy and intraoperative frozen section in the management of bladder cancer, tailoring to the bladder tumor stage is still not well defined and universally accepted. This review discusses the current understanding of the biology and histological patterns of pTCC and their clinical significance and management options. A rational approach for management of pTCC in patients with bladder cancer will be proposed on the basis of our experience and our review of literature.

Publication types

  • Review

MeSH terms

  • Biopsy
  • Carcinoma in Situ / pathology
  • Carcinoma, Transitional Cell / pathology*
  • Carcinoma, Transitional Cell / therapy
  • Humans
  • Male
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Prognosis
  • Prostatic Neoplasms / pathology*
  • Prostatic Neoplasms / therapy
  • Urinary Bladder Neoplasms / pathology*
  • Urinary Bladder Neoplasms / therapy